Scientific Publications
Publications
Poster: A First in Human Study of AO-176, a Highly Differentiated Anti-CD47 Antibody, in Patients with Advanced Solid Tumors
Abstract: A First-in-Human Study of AO-176, a Highly Differentiated Anti-CD47 Antibody, in Patients with Advanced Solid Tumors
Novel SIRPα Antibodies that Induce Single-Agent Phagocytosis of Tumor Cells while Preserving T Cells
Publication: The Journal of Immunology.
Authors: , , , , , and
Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding
Publication: Molecular Cancer Therapeutics. Published first online on December 26, 2019.
Authors: Robyn J. Puro, Myriam N. Bouchlaka, Ronald R. Hiebsch, Benjamin J. Capoccia, Michael J. Donio, Pamela T. Manning, William A. Frazier, Robert W. Karr, and Daniel S. Pereira
Poster Presentations
AACR Annual Meeting 2021
Poster Presentation: The differentiated CD47 monoclonal antibody AO-176 exhibits significant in vivo activity against xenograft models of pediatric acute lymphoblastic leukemia (ALL)
AACR Annual Meeting 2021
Poster Presentation: AO-176, a highly differentiated clinical stage anti-CD47 antibody, is efficacious in pre-clinical models of lymphoma
ASH Annual Meeting and Exposition 2020
Poster Presentation: AO-176, a Highly Differentiated Clinical Stage Anti-CD47 Antibody, Exerts Potent Anti-Tumor Activity in Preclinical Models of Multiple Myeloma as a Single Agent and in Combination With Approved Therapeutics
ASH Annual Meeting and Exposition 2020
Poster Presentation: Pre-clinical Combination of AO-176, a Highly Differentiated Clinical Stage CD47 Antibody, with Either Azacitidine or Venetoclax Significantly Enhances DAMP Induction and Phagocytosis of Acute Myeloid Leukemia
ASH Annual Meeting & Exposition 2019
Poster Presentation: Highly Differentiated Anti-CD47 Antibody AO-176, Potently Inhibits Hematologic Malignancies Alone and in Combination in Pre-Clinical Models
SITC Annual Meeting 2019
Poster Presentation: Novel SIRP Antibodies with Differentiated Characteristics for Targeting Innate Immunity in Cancer
AACR-NCI-EORTC EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019
Poster Presentation: AO-176, a highly differentiated humanized anti-CD47 antibody, exhibits single-agent and combination anti-tumor efficacy with chemotherapy and targeted antibodies in preclinical models (Abstract #: B100)
AACR Annual Meeting 2019
Poster Presentation: AO-176, a normal cell sparing humanized anti-CD47 antibody
AACR Annual Meeting 2019
Poster Presentation: Evaluation of novel anti-SIRP antibodies as potential cancer therapeutics
ASH Annual Meeting & Exposition 2018
Poster Presentation: Therapeutic potential of AO-176, a next-generation humanized CD47 antibody, for hematologic malignancies